Lead: First Trimester Use of Buprenorphine or Methadone

30/01/2024 6 min Episodio 99
Lead: First Trimester Use of Buprenorphine or Methadone

Listen "Lead: First Trimester Use of Buprenorphine or Methadone"

Episode Synopsis

Lead Story:
First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations 🔓
JAMA Internal Medicine
In this cohort study of 9,514 pregnancies with first-trimester buprenorphine exposure and 3,846 with methadone exposure, the prevalence of congenital malformations overall and several malformation subtypes was lower among pregnant individuals treated with buprenorphine compared with methadone, except for gastrointestinal malformations. There was an 18% relative risk reduction for malformations overall, which translates to 1 less event per 100 patients treated with buprenorphine vs methadone.  When determining optimal treatment for pregnant individuals with opioid use disorder, considerations should include the relative risk reduction for malformations overall with buprenorphine vs methadone, as well as treatment access, previous success on a particular treatment, and the likelihood of retention in treatment.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

More episodes of the podcast This Week in Addiction Medicine from ASAM